Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy

NCT07706088 on ClinicalTrials.gov · last registry update 2026-07-15

Registered but not yet open, with 40 participants planned. Due to report 1 July 2028, alongside 23 other tracked readouts that quarter. Primary outcome, as filed: To assess the percent change in CNFD compared to baseline. Sponsors move these dates routinely; any movement since this site started watching is listed below.

Status: NOT_YET_RECRUITING
Phase: P4
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh
Sponsor type: Other
Enrollment: 40
Started: 2026-07
Primary completion: 2028-07-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

To assess the percent change in CNFD compared to baseline

Conditions studied

Neuropathy, Small Fiber · Diabete Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.